Expert Review of Clinical Pharmacology

Papers
(The H4-Index of Expert Review of Clinical Pharmacology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion53
Effects of the augmentation with quetiapine or olanzapine on the metabolism of duloxetine: a retrospective analysis52
A review of current and emerging therapies in breast cancer: implications for older adults40
Renin angiotensin aldosterone inhibitors in the treatment of proteinuria in children with congenital anomalies of the kidney and urinary tract: more evidence needed39
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?36
Clinical pharmacology of antiplatelet drugs35
Reducing the risk of death – a possible outcome in COPD patients34
Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions34
Sparsentan: a dual endothelin and angiotensin II receptor antagonist approved for IgA nephropathy33
Strategies for lowering lipoprotein(a): a spotlight on novel pharmacological treatments31
A simulation study to assess the influence of population pharmacokinetic model selection on Bayesian forecasting of vancomycin exposure in preterm neonates29
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies28
Management of polypharmacy through deprescribing in older patients: a review of the role of AI tools27
Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?26
What is the potential for abuse of lisdexamfetamine in adults? A preclinical and clinical literature review and expert opinion24
Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome24
Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis23
Cannabidiol drug interaction considerations for prescribers and pharmacists22
JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review22
Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria22
Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection21
Medical management of pediatric chronic rhinosinusitis21
Amylin analogs for the treatment of obesity without diabetes: present and future21
0.29409980773926